Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway

Rujia Fan, Yiying Wang, Yue Wang, Li Wei, Wenxin - Zheng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Progestin is commonly used for young patients suffering from endometrial hyperplasia or cancer. However, there is approximately 30% failure rate with unclear mechanism. We investigated if Nrf2-survivin pathway contributes the progestin resistance (PR) in this setting. Current study detected Nrf2 and survivin protein expression in post progestin treated endometrial tissue samples by using immunohistochemistry. Transfection of Nrf2 and survivin into endometrial cancer cells in vitro was done to determine the roles of Nrf2 and survivin in progestin resistance. Silence of survivin was then performed to explore if Nrf2-driven progestin resistance is mediated by survivin. Medorxyprogesterone acetate (MPA) and metformin were applied to examine the cellular proliferations under the controlled conditions. Overexpression of survivin and Nrf2 were found in progestin-resistant endometrial samples as well as in those areas with only partial responses after MPA treatment. In contrast, all responded endometrial tissue with complete decidualization showed negative expression of these two biomarkers. Exogenous overexpression of Nrf2 and survivin resulted in progestin resistance. In addition, reduction of survivin in endometrial cancer cells overcame the Nrf2 overexpression induced progestin resistance. Furthermore, Nrf2 and survivin expressions were effectively suppressed after withdrawal of MPA. Interestingly, metformin increased the progestin sensitivity by down regulation of Nrf2 and survivin. The findings suggest that dysregulation of Nrf2-survivin may represent part of the molecular mechanisms of progestin resistance in endometrial cancer. Detecting survivin and Nrf2 may predict progestin resistance, while targeting Nrf2 and survivin may represent a promising prevention and treatment strategy for endometrial cancer.

Original languageEnglish (US)
Article numberAJTR0042451
Pages (from-to)1483-1491
Number of pages9
JournalAmerican Journal of Translational Research
Volume9
Issue number3
StatePublished - 2017
Externally publishedYes

Fingerprint

Progestins
Endometrial Neoplasms
Acetates
Metformin
Cells
Tissue
Endometrial Hyperplasia
Biomarkers
Transfection
Down-Regulation
Immunohistochemistry
Cell Proliferation

Keywords

  • Endometrial cancer
  • Endometrial hyperplasia
  • Endometrial precancer
  • Nrf2
  • Progestin resistance
  • Survivin

ASJC Scopus subject areas

  • Medicine(all)
  • Molecular Medicine
  • Clinical Biochemistry
  • Cancer Research

Cite this

Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway. / Fan, Rujia; Wang, Yiying; Wang, Yue; Wei, Li; Zheng, Wenxin -.

In: American Journal of Translational Research, Vol. 9, No. 3, AJTR0042451, 2017, p. 1483-1491.

Research output: Contribution to journalArticle

@article{5b41dd4b10e34d8f8d1614557cb8385a,
title = "Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway",
abstract = "Progestin is commonly used for young patients suffering from endometrial hyperplasia or cancer. However, there is approximately 30{\%} failure rate with unclear mechanism. We investigated if Nrf2-survivin pathway contributes the progestin resistance (PR) in this setting. Current study detected Nrf2 and survivin protein expression in post progestin treated endometrial tissue samples by using immunohistochemistry. Transfection of Nrf2 and survivin into endometrial cancer cells in vitro was done to determine the roles of Nrf2 and survivin in progestin resistance. Silence of survivin was then performed to explore if Nrf2-driven progestin resistance is mediated by survivin. Medorxyprogesterone acetate (MPA) and metformin were applied to examine the cellular proliferations under the controlled conditions. Overexpression of survivin and Nrf2 were found in progestin-resistant endometrial samples as well as in those areas with only partial responses after MPA treatment. In contrast, all responded endometrial tissue with complete decidualization showed negative expression of these two biomarkers. Exogenous overexpression of Nrf2 and survivin resulted in progestin resistance. In addition, reduction of survivin in endometrial cancer cells overcame the Nrf2 overexpression induced progestin resistance. Furthermore, Nrf2 and survivin expressions were effectively suppressed after withdrawal of MPA. Interestingly, metformin increased the progestin sensitivity by down regulation of Nrf2 and survivin. The findings suggest that dysregulation of Nrf2-survivin may represent part of the molecular mechanisms of progestin resistance in endometrial cancer. Detecting survivin and Nrf2 may predict progestin resistance, while targeting Nrf2 and survivin may represent a promising prevention and treatment strategy for endometrial cancer.",
keywords = "Endometrial cancer, Endometrial hyperplasia, Endometrial precancer, Nrf2, Progestin resistance, Survivin",
author = "Rujia Fan and Yiying Wang and Yue Wang and Li Wei and Zheng, {Wenxin -}",
year = "2017",
language = "English (US)",
volume = "9",
pages = "1483--1491",
journal = "American Journal of Translational Research",
issn = "1943-8141",
publisher = "e-Century Publishing Corporation",
number = "3",

}

TY - JOUR

T1 - Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway

AU - Fan, Rujia

AU - Wang, Yiying

AU - Wang, Yue

AU - Wei, Li

AU - Zheng, Wenxin -

PY - 2017

Y1 - 2017

N2 - Progestin is commonly used for young patients suffering from endometrial hyperplasia or cancer. However, there is approximately 30% failure rate with unclear mechanism. We investigated if Nrf2-survivin pathway contributes the progestin resistance (PR) in this setting. Current study detected Nrf2 and survivin protein expression in post progestin treated endometrial tissue samples by using immunohistochemistry. Transfection of Nrf2 and survivin into endometrial cancer cells in vitro was done to determine the roles of Nrf2 and survivin in progestin resistance. Silence of survivin was then performed to explore if Nrf2-driven progestin resistance is mediated by survivin. Medorxyprogesterone acetate (MPA) and metformin were applied to examine the cellular proliferations under the controlled conditions. Overexpression of survivin and Nrf2 were found in progestin-resistant endometrial samples as well as in those areas with only partial responses after MPA treatment. In contrast, all responded endometrial tissue with complete decidualization showed negative expression of these two biomarkers. Exogenous overexpression of Nrf2 and survivin resulted in progestin resistance. In addition, reduction of survivin in endometrial cancer cells overcame the Nrf2 overexpression induced progestin resistance. Furthermore, Nrf2 and survivin expressions were effectively suppressed after withdrawal of MPA. Interestingly, metformin increased the progestin sensitivity by down regulation of Nrf2 and survivin. The findings suggest that dysregulation of Nrf2-survivin may represent part of the molecular mechanisms of progestin resistance in endometrial cancer. Detecting survivin and Nrf2 may predict progestin resistance, while targeting Nrf2 and survivin may represent a promising prevention and treatment strategy for endometrial cancer.

AB - Progestin is commonly used for young patients suffering from endometrial hyperplasia or cancer. However, there is approximately 30% failure rate with unclear mechanism. We investigated if Nrf2-survivin pathway contributes the progestin resistance (PR) in this setting. Current study detected Nrf2 and survivin protein expression in post progestin treated endometrial tissue samples by using immunohistochemistry. Transfection of Nrf2 and survivin into endometrial cancer cells in vitro was done to determine the roles of Nrf2 and survivin in progestin resistance. Silence of survivin was then performed to explore if Nrf2-driven progestin resistance is mediated by survivin. Medorxyprogesterone acetate (MPA) and metformin were applied to examine the cellular proliferations under the controlled conditions. Overexpression of survivin and Nrf2 were found in progestin-resistant endometrial samples as well as in those areas with only partial responses after MPA treatment. In contrast, all responded endometrial tissue with complete decidualization showed negative expression of these two biomarkers. Exogenous overexpression of Nrf2 and survivin resulted in progestin resistance. In addition, reduction of survivin in endometrial cancer cells overcame the Nrf2 overexpression induced progestin resistance. Furthermore, Nrf2 and survivin expressions were effectively suppressed after withdrawal of MPA. Interestingly, metformin increased the progestin sensitivity by down regulation of Nrf2 and survivin. The findings suggest that dysregulation of Nrf2-survivin may represent part of the molecular mechanisms of progestin resistance in endometrial cancer. Detecting survivin and Nrf2 may predict progestin resistance, while targeting Nrf2 and survivin may represent a promising prevention and treatment strategy for endometrial cancer.

KW - Endometrial cancer

KW - Endometrial hyperplasia

KW - Endometrial precancer

KW - Nrf2

KW - Progestin resistance

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=85016428164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016428164&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 1483

EP - 1491

JO - American Journal of Translational Research

JF - American Journal of Translational Research

SN - 1943-8141

IS - 3

M1 - AJTR0042451

ER -